Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyKimberly Davies, Deborah A. Freedman-Cass, Robert J. Hayashi et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 67
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug eraLianna J. Marks, Catherine Aftandilian, Victor Ritter et al.|Blood Advances|2025Cited by 9
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08Jamie E. Flerlage, M Link, Angela M. Feraco et al.|Blood|2026Cited by 2
Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium’s phase 2 study cHOD17 (NCT03755804).Jamie E. Flerlage, Angela M. Feraco, Yiwang Zhou et al.|Journal of Clinical Oncology|2025Cited by 0
METABOLIC-ONLY RESPONSE ASSESSMENT ALLOWS FOR OMISSION OF RESIDUAL NODE RADIATION THERAPY (RNRT) FOR THE MAJORITY OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) WHILE MAINTAINING EXCELLENT EVENT FREE (EFS) AND OVERALL SURVIVAL (OS): A REPORT FROM THE PEDIATRIC HODGKIN CONSORTIUM’S PHASE 2 STUDY cHOD17 (NCT03755804)Jamie E. Flerlage, Matthew J. Ehrhardt, Angela M. Feraco et al.|Leukemia Research|2025Cited by 0